Brokerages Set Entrada Therapeutics, Inc. (NASDAQ:TRDA) Target Price at $17.50

Posted by Brian Himes on Jun 20th, 2026

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) has been given a consensus rating of “Hold” by the six research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $17.50.

Several equities research analysts recently commented on TRDA shares. HC Wainwright cut Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Guggenheim cut their price target on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Monday, June 8th. Weiss Ratings cut Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Roth Mkm set a $10.00 price target on Entrada Therapeutics in a report on Friday, May 8th. Finally, Cantor Fitzgerald began coverage on Entrada Therapeutics in a report on Wednesday, April 1st. They issued an “overweight” rating for the company.

View Our Latest Research Report on Entrada Therapeutics

Insiders Place Their Bets

In other Entrada Therapeutics news, COO Nathan J. Dowden sold 15,000 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $15.33, for a total transaction of $229,950.00. Following the completion of the sale, the chief operating officer owned 198,588 shares of the company’s stock, valued at $3,044,354.04. This trade represents a 7.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Natarajan Sethuraman sold 25,907 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $15.39, for a total value of $398,708.73. Following the sale, the insider directly owned 216,317 shares of the company’s stock, valued at approximately $3,329,118.63. This trade represents a 10.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 43,407 shares of company stock worth $661,034 in the last three months. 9.49% of the stock is owned by insiders.

Institutional Investors Weigh In On Entrada Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TRDA. Allspring Global Investments Holdings LLC boosted its position in shares of Entrada Therapeutics by 9.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock worth $176,000 after buying an additional 1,560 shares during the period. Alliancebernstein L.P. boosted its position in shares of Entrada Therapeutics by 7.1% during the third quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock worth $141,000 after buying an additional 1,620 shares during the period. Great Lakes Advisors LLC boosted its position in shares of Entrada Therapeutics by 5.5% during the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock worth $445,000 after buying an additional 2,239 shares during the period. Quadrature Capital Ltd boosted its position in shares of Entrada Therapeutics by 13.5% during the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock worth $209,000 after buying an additional 2,424 shares during the period. Finally, First Trust Advisors LP boosted its position in shares of Entrada Therapeutics by 3.6% during the second quarter. First Trust Advisors LP now owns 75,120 shares of the company’s stock worth $505,000 after buying an additional 2,631 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Stock Performance

NASDAQ:TRDA opened at $7.09 on Monday. Entrada Therapeutics has a one year low of $4.93 and a one year high of $16.45. The stock has a market cap of $275.23 million, a PE ratio of -1.78 and a beta of -0.26. The stock has a 50 day moving average price of $9.15 and a 200 day moving average price of $10.59.

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.11. Entrada Therapeutics had a negative return on equity of 51.22% and a negative net margin of 2,895.05%.The firm had revenue of $0.88 million during the quarter, compared to analysts’ expectations of $2.92 million. As a group, analysts predict that Entrada Therapeutics will post -4.12 earnings per share for the current fiscal year.

Entrada Therapeutics Company Profile

(Get Free Report)

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

Analyst Recommendations for Entrada Therapeutics (NASDAQ:TRDA)

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.